What is interstitial cystitis?
Interstitial cystitis (also called bladder pain syndrome) is a chronic urological condition characterised by bladder pain, urinary urgency, and frequent urination without identifiable infection or other defined cause. Studied in a 2024 BPC-157 pilot trial — one of the few human-cohort BPC-157 research contexts.
What the research literature says
Interstitial cystitis (IC) is a chronic bladder-pain condition with poorly-understood pathophysiology. The condition affects predominantly women and is characterised by suprapubic pain associated with bladder filling, urinary urgency, and increased frequency of urination. Conventional treatment options are limited and symptomatic; new therapeutic frameworks are an active research area.
A 2024 BPC-157 pilot trial in interstitial cystitis patients (PMID 39325560) is among the small set of published human-subject BPC-157 studies. The trial framework explores the compound’s research-context relevance to the tissue-repair and inflammation-modulation pharmacology that characterises the preclinical BPC-157 literature. As with all human BPC-157 research, the evidence base is limited compared to the extensive preclinical literature consolidated in the Sikiric reviews (PMID 38980576 gastrointestinal; PMID 34267654 wound healing; PMID 38675421 pleiotropic activity).
The compound is not approved by any major regulator for interstitial cystitis or any other clinical indication; the published research operates within the preclinical-and-pilot-clinical-trial framework.
Why this matters in research context
Interstitial cystitis matters in peptide-research contexts as one of the few human-cohort contexts in which BPC-157 has been studied. Researchers tracking the compound’s translation from preclinical to human-research framing should reference the 2024 pilot trial as the leading-edge data point. The trial does not establish efficacy at the clinical-development level but documents the research-context relevance.
Related compounds
- BPC-157 10mg — the compound studied in the 2024 IC pilot trial
Related research questions
References
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
- Gwyer D et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol 2021;12:627533. [PMID 34267654]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. BPC-157 is sold strictly as a research-grade reagent for laboratory and bench research applications.